ROS1 is a therapeutic target in NSCLC, with gene fusions occurring in 1–2%
Patients with ROS1+ NSCLC require an effective treatment with both systemic and central nervous system (CNS) activity3–6
of patients with advanced ROS1+ NSCLC have CNS metastases at
of patients have CNS as their first and only site of progression3,7
The most common sites of metastasis for patients with all types of stage IV lung cancer8
(36% for ROS1+ NSCLC)3
Despite advances in therapy for ROS1+ NSCLC, additional treatment options are needed to improve clinical outcomes3
High-quality molecular testing, such as FISH and NGS, is needed to confirm patients with actionable ROS1 gene fusions9
- NGS is emerging as a technology with the sensitivity and accuracy necessary to identify all ROS1 gene fusions with a single test9,13–19
Genetic rearrangements leading to constitutive expression of ROS1 have been identified in a number of tumour types, including NSCLC20–22
In ROS1+ NSCLC, the ROS1 gene undergoes a chromosomal rearrangement, resulting in the fusion of the tyrosine kinase domain of ROS1 with one of several partner proteins22
The resulting ROS1-fusion kinases are constitutively activated to trigger growth and survival signalling pathways that drive cellular proliferation22
CNS, central nervous system; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription polymerase chain reaction.
Bergethon K, et al. J Clin Oncol 2012;30:863–870.
Dugay F, et al. Oncotarget 2017;8:53336–53351.
Patil T, et al. J Thorac Oncol 2018;13:1717–1726.
Gainor JF, et al. JCO Precis Oncol 2017. DOI: 10.1200/PO.17.00063.
Mazières J, et al. J Clin Oncol 2015;33:992–999.
Wu YL, et al. J Clin Oncol 2018;36:1405–1411.
Xu H, et al. Cancer Med 2020;9:3328–3336.
Oikawa A, et al. Oncol Lett 2012;3:629–634.
Bubendorf L, et al. Virchows Arch 2016;469:489–503.
Planchard D. Ann Oncol 2018;29:iv192–iv237.
International Association for the Study of Lung Cancer. IASLC Atlas of ALK and ROS1 testing in lung cancer. Available at: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-alk-and-ros1-testing-lung-cancer (Accessed November 2020).
Rossi G, et al. Lung Cancer (Auckl) 2017:8:45–55.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. V.6.2020, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed November 2020).
Diaz L, Bardelli A. J Clin Oncol 2014;32:579–586.
Shan L, et al. PLoS One 2015;10:e0120422.
Cao B, et al. Onco Targets Ther 2016;31:131–138.
Zheng Z, et al. Nat Med 2014;20:1479–1484.
Drilon A, et al. Clin Cancer Res 2015;21:3631–3639.
Grada A, Weinbrecht K. J Invest Dermatol 2013;133:e11.
Birchmeier C, et al. Proc Natl Acad Sci U S A 1987;84: 9270–9274.
Rikova K, et al. Cell 2007;131:1190–1203.
Gainor J, Shaw A. Oncologist 2013;18:865–875.